Key clinical point: The gene therapy LentiGlobin reduced transfusion dependence in children and young adults with non-beta0/beta0 thalassemia in two clinical trials.
Major finding: In a phase 1/2 trial, 8 of 10 of patients achieved transfusion independence at a median follow-up of 36 months. In a phase 3 trial, transfusion independence was achieved by 2 of 3 patients with follow-up of at least 12 months.
Study details: A phase 1/2 trial of 10 patients and a phase 3 trial of 16 patients with non-beta0/beta0 thalassemia.
Disclosures: The presenter reported advisory board engagement with bluebird bio, which sponsored both trials.
Olson TS et al. ASPHO 2019, Abstract 2002.
This Week's Must Reads
Must Reads in Anemia
Gene therapy reverses sickle cell phenotype in small study, Esrick EB et al. ASH 2018, Abstract 1023
Sickle cell pain: Opioids appear safe for inpatients, Akinboro OA et al. ASH 2018, Abstract 315
Sickle cell: Daily hydroxyurea safe in African children, Tshilolo L et al. ASH 2018, Abstract 3